Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/1465
Título : Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
Autor : Cardinali, Daniel Pedro 
Golombek, Diego A. 
Rosenstein, Ruth E. 
Brusco, Luis I. 
Vigo, Daniel Eduardo 
Palabras clave : MEDICINAINSOMNIOMELATONINASUEÑOBIOMEDICINABENZODIACEPINASABUSO DE DROGAS
Fecha de publicación : 2016
Editorial : Elsevier
Cita : Cardinali D. P., et al. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse [en línea]. Postprint del documento publicado en Pharmacological Research. 2016, 109. doi: 10.1016/j.phrs.2015.08.016. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1465
Resumen : Abstract: The abuse of benzodiazepine (BZP) and Z drugs has become, due to the tolerance and dependence theyproduce, a serious public health problem. Thirty years ago, we demonstrated in experimental animalsthe interaction of melatonin with central BZD receptors, and in 1997 we published the first series ofelderly patients who reduced BZP consumption after melatonin treatment. Almost every single neuron inthe hypothalamic suprachiasmatic nuclei (SCN), the central pacemaker of the circadian system, contains-aminobutyric acid (GABA) and many results in animals point out to a melatonin interaction with GABA-containing neurons. In addition, central-type BZD antagonism, that obliterates GABAAreceptor function,blunted most behavioral effects of melatonin including sleep. Melatonin is involved in the regulation ofhuman sleep. This is supported by the temporal relationship between the rise of plasma melatonin levelsand sleep propensity as well as by the sleep-promoting effects of exogenously administered melatonin.Both meta-analyses and consensus agreements give support to the therapeutic use of melatonin in sleepdisorders. This action is attributed to MT1and MT2melatoninergic receptors localized in the SCN, as wellas in other brain areas. This review discusses available data on the efficacy of melatonin to curtail chronicBZD/Z drug use in insomnia patients. A major advantage is that melatonin has a very safe profile, it isusually remarkably well tolerated and, in some studies, it has been administered to patients at very largedoses and for long periods of time, without any potentiality of abuse. Further studies on this applicationof melatonin are warranted.
URI : https://repositorio.uca.edu.ar/handle/123456789/1465
ISSN : 1096-1186 (online)
1043-6618 (impreso)
Disciplina: MEDICINA
DOI: 10.1016/j.phrs.2015.08.016
Derechos: Acceso Abierto. 1 año de embargo
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
alterations-metabolism-diurnal-rythms.pdf504,56 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

93
checked on Feb 28, 2021

Download(s)

229
checked on Feb 28, 2021

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons